Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells

International Journal of Oncology

Volumn 37, Issue 4, 2010, Pages 869-877

  Kinoshita, Keiichi ^a,b   Nakagawa, Koji ^b   Hamada, Jun Ichi ^b   Hida, Yasuhiro ^a   Tada, Mitsuhiro ^b   Kondo, Satoshi ^a   Moriuchi, Tetsuya ^b  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Cancer associated stromal fibroblasts; Conditioned media; Imatinib mesylate; Lung cancer; PDGF; Proliferation stimulating

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ASSOCIATED STROMAL FIBROBLAST; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FIBROBLAST; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 77956543006     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000738     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Asamura H, Goya T, Koshiishi Y, et al: A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 3: 46-52, 2008.
3. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717, 1997. (Pubitemid 27260107)
4. Tsuboi M, Ohira T, Saji H, et al: The present status of post-operative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg 13: 73-77, 2007.
5. Tremblay G: Stromal aspects of breast carcinoma. Exp Mol Pathol 31: 248-260, 1979.
6. Fidler IJ: Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 50: 6130-6138, 1990.
7. Tlsty TD: Stromal cells can contribute oncogenic signals. Semin Cancer Biol 11: 97-104, 2001.
8. Bhowmick NA, Neilson EG and Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337, 2004.
9. Gabbiani G, Ryan GB and Majne G: Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 27: 549-550, 1971.
10. Ronnov-Jessen L, Petersen OW, Koteliansky VE and Bissell MJ: The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 95: 859-873, 1995.
11. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD and Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59: 5002-5011, 1999.
12. Okusa Y, Ichikura T and Mochizuki H: Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma. Cancer 85: 1033-1038, 1999.
13. Orimo A, Gupta PB, Sgroi DC, et al: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348, 2005.
14. Hasebe T, Sasaki S, Imoto S and Ochiai A: Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast. Mod Pathol 14: 325-337, 2001.
15. Forsberg K, Valyi-Nagy I, Heldin CH, Herlyn M and Westermark B: Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci USA 90: 393-397, 1993.
16. Lindmark G, Sundberg C, Glimelius B, Pahlman L, Rubin K and Gerdin B: Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab Invest 69: 682-689, 1993. (Pubitemid 24026849)
17. Shao ZM, Nguyen M and Barsky SH: Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 19: 4337-4345, 2000.
18. Betsholtz C, Karlsson L and Lindahl P: Developmental roles of platelet-derived growth factors. Bioessays 23: 494-507, 2001.
19. Bhardwaj B, Klassen J, Cossette N, et al: Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma. Clin Cancer Res 2: 773-782, 1996.
20. Kawai T, Hiroi S and Torikata C: Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab Invest 77: 431-436, 1997.
21. Ebert M, Yokoyama M, Friess H, Kobrin MS, Buchler MW and Korc M: Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer 62: 529-535, 1995.
22. Jones RL and Judson IR: The development and application of imatinib. Expert Opin Drug Saf 4: 183-191, 2005.
23. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566, 1996. (Pubitemid 126664202)
24. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA and Zigler AJ: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925-932, 2000.
25. Buchdunger E, Cioffi CL, Law N, et al: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295: 139-145, 2000.
26. McGary EC, Weber K, Mills L, et al: Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 8: 3584-3591, 2002.
27. Matei D, Chang DD and Jeng MH: Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res 10: 681-690, 2004.
28. Mueller L, Goumas FA, Himpel S, Brilloff S, Rogiers X and Broering DC: Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases. Cancer Lett 250: 329-338, 2007.
29. Gioni V, Karampinas T, Voutsinas G, et al: Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts. Mol Cancer Res 6: 706-714, 2008.
30. Pietras K, Pahler J, Bergers G and Hanahan D: Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 5: e19, 2008.
31. Micke P and Ostman A: Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 45 (Suppl. 2): S163-S175, 2004.
32. Aono Y, Nishioka Y, Inayama M, et al: Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 171: 1279-1285, 2005.
33. Abdollahi A, Li M, Ping G, et al: Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201: 925-935, 2005.
34. Nakamura T, Matsumoto K, Kiritoshi A, Tano Y and Nakamura T: Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res 57: 3305-3313, 1997.
35. Gmyrek GA, Walburg M, Webb CP, et al: Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol 159: 579-590, 2001. (Pubitemid 32751088)
36. Giri D, Ropiquet F and Ittmann M: Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5: 1063-1071, 1999.
37. Fukumura D, Xavier R, Sugiura T, et al: Tumor induction of VEGF promoter activity in stromal cells. Cell 94: 715-725, 1998.
38. Dong J, Grunstein J, Tejada M, et al: VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 23: 2800-2810, 2004.
39. Kitadai Y, Sasaki T, Kuwai T, et al: Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. Int J Cancer 119: 2567-2574, 2006.
40. Tejada ML, Yu L, Dong J, et al: Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Clin Cancer Res 12: 2676-2688, 2006.
41. Sundberg C, Branting M, Gerdin B and Rubin K: Tumor cell and connective tissue cell interactions in human colorectal adenocarcinoma. Transfer of platelet-derived growth factor- AB/BB to stromal cells. Am J Pathol 151: 479-492, 1997. (Pubitemid 27330067)
42. Coltrera MD, Wang J, Porter PL and Gown AM: Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res 55: 2703-2708, 1995.
43. Ronnov-Jessen L, van Deurs B, Celis JE and Petersen OW: Smooth muscle differentiation in cultured human breast gland stromal cells. Lab Invest 63: 532-543, 1990.
44. Micke P and Ostman A: Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 9: 1217-1233, 2005.
45. Heldin CH, Rubin K, Pietras K and Ostman A: High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 4: 806-813, 2004.
46. Less JR, Posner MC, Boucher Y, Borochovitz D, Wolmark N and Jain RK: Interstitial hypertension in human breast and colorectal tumors. Cancer Res 52: 6371-6374, 1992.
47. Boucher Y, Kirkwood JM, Opacic D, Desantis M and Jain RK: Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 51: 6691-6694, 1991.
48. Gutmann R, Leunig M, Feyh J, et al: Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res 52: 1993-1995, 1992.
49. Pietras K, Rubin K, Sjoblom T, et al: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62: 5476-5484, 2002.
50. Vlahovic G, Ponce AM, Rabbani Z, et al: Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer 97: 735-740, 2007.